Abstract Details

Title Mesenchymal Stem Cells and Autoimmune Diseases: The Case of Multiple Sclerosis

Topic MS and Related Diseases

Presentation(s) P05 - (-)

Poster/Presentation
Number 178

Objective

Background BACKGROUND: Preclinical studies suggest the transplantation of mesenchymal stem cells (MSCs) as a possible therapy in multiple sclerosis (MS), in addition the transplantation of autologous MSCs would bypass the risks associated to the use of an allogenic MSC Bank. Here we analyse the characteristics of MSCs isolated from MS patients compared to those isolated from healthy donors (HD) and we show that IP10 production upon LPS stimulation is different between the two groups.

Design/Methods DESIGN/METHODS: (BM) MSCs isolated from 12 MS patients, before and 3 after AHSCT and 20 HD were investigated by Flow cytometry, proliferation and colony forming unit (CFU) number, differentiation ability, immunomodulation on T cell proliferative response, toll like receptor (TLR) expression, cytokine production and cell signalling pathways.

Results RESULTS: MS MSCs show significant (p<0.003) increased production of IP10, a T cell recall chemokine, and increased phosphorylation of p38, CREB, JNK, and STAT1. All tests were performed after TLR4 stimulation. Interestingly, the basal level of activation for all these factors was higher in MS MSCs, except for STAT1. At the same time, MSC immunomodulatory action was not altered. This was preliminary confirmed in post AHSCT MS MSCs.

Conclusions CONCLUSIONS: the increased production of IP10 in MS MSCs is in accordance with an altered basal activation state and within increased phosphorylation after TLR4 stimulation of factors forming signalling cascade responsible of IP10 production and secretion that remains after AHSCT. This may represent a disease marker or an effect of previous therapies or both. Our data indicate that an attentive evaluation of MSCs is mandatory in MS and autoimmune diseases before their translation into therapy.

Authors/Disclosures
PRESENTER	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file
Luca Massacesi (Osp. Policlinico Careggi)	The institution of Luca Massacesi has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Biogen. Luca Massacesi has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Biogen. Luca Massacesi has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Novartis. Luca Massacesi has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Roche. Luca Massacesi has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Merck-Serono. Luca Massacesi has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Johnson and Johnson. Luca Massacesi has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Alexion. Luca Massacesi has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Horizon. The institution of Luca Massacesi has received research support from Tuscan Region Government. The institution of Luca Massacesi has received research support from Sanofi. The institution of Luca Massacesi has received research support from Roche. Luca Massacesi has received research support from Merck-Serono.
	No disclosure on file
	No disclosure on file

��ɫ��

��ɫ��